Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ Scribed by W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachselt; P. Richter; V. Schirmer; A. Schulze; R. Šubert; B. Harksel; N. Grobe; E. Stelzer; M. Schulze; A. Bittrich; M. Freund; R. Pasold; Th. Friedrich; W. Helbig; D. Niederwieser

• Publisher: Springer-Verlag
• Year: 2006
• Tongue: English
• Weight: 344 KB
• Volume: 132
• Category: Article
• ISSN: 1432-1335
• DOI: 10.1007/s00432-005-0074-4